May 28 (Reuters) - Drug developer iTeos Therapeutics ITOS.O said on Wednesday it plans to wind down its operations and explore selling its assets, including experimental cancer treatments and an obesity program.
Earlier this month, Britain's GSK GSK.L and iTeos Therapeutics said they have stopped developing an experimental lung cancer drug, belrestotug, after it failed to stop the disease from progressing in two studies.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Shreya Biswas)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。